Introduction
============

Three-vessel disease (TVD), characterized by significant stenosis in all three major coronary arteries, is a severe form of coronary artery disease (CAD) that confers a substantial risk of mortality^[@bib1])^. Risk stratification is important to identify high-risk patients with TVD who require intensive treatment and close follow-up. With this aim, the SYNTAX score (SS) and SYNTAX score II (SSII) have been established for risk assessment in patients with TVD^[@bib2],\ [@bib3])^. However, accurate risk stratification has always been challenging. Identification of additional biomarkers with prognostic significance may be able to improve the predictability of the established models.

Endothelin-1 (ET-1), a 21-amino acid peptide, is the most powerful constrictor of human vessels discovered to date^[@bib4])^. It is primarily produced and released by vascular endothelial cells and can cause endothelial dysfunction and inflammation, which may contribute to atherosclerotic plaque formation^[@bib5])^. However, clinical use of ET-1 as a biomarker is limited because of its instability in plasma^[@bib6])^. As a precursor of ET-1, big ET-1 is relatively stable and can be used as an alternative approach for indirect estimation of ET-1 release^[@bib6])^. Big ET-1 level was shown to be correlated with disease severity and clinical outcome in patients with acute myocardial infarction (MI) and stable CAD^[@bib7]--[@bib10])^. However, its clinical implications have not been evaluated in the setting of TVD with advanced coronary atheroma burden.

Aim
===

The present study aimed to assess the prognostic value of plasma big ET-1 level in patients with TVD.

Methods
=======

Study Design and Participants
-----------------------------

Data were obtained from a large prospective cohort study in which a total of 8,943 patients with TVD were consecutively enrolled from April 2004 to February 2011 at Fuwai Hospital, Chinese Academy of Medical Sciences (Beijing, China). Eligible patients were those who had TVD, defined as angiographically confirmed stenosis of ≥ 50% in all three main epicardial coronary arteries (left anterior descending, left circumflex, and right coronary arteries) with or without involvement of the left main artery, and were willing to undergo follow-up. There were no prespecified exclusion criteria. No treatment intervention was dictated by the protocol for the observational study. Patients received medical therapy (MT) alone, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) according to contemporary practice guidelines and their preferences^[@bib11],\ [@bib12])^. After enrollment, the patients were followed up in accordance with the study protocol. Baseline and procedural data for all participants were collected into a database by independent clinical research coordinators.

The study complied with the principles of the Declaration of Helsinki and was approved by the Review Board of Fuwai Hospital. Written informed consent was obtained from all participants.

Definitions
-----------

The concentrations of plasma big ET-1 were measured in fasting venous blood samples after admission for coronary angiography, using a highly sensitive and specific commercial sandwich enzyme immunoassay (BI-20082H; Biomedica, Wien, Austria). The SS was calculated using an online calculator (<http://www.syntaxscore.com>) by a dedicated research group blinded to the clinical data. Calculation of the SSII was based on two anatomical variables and six clinical variables^[@bib3])^. Creatinine clearance was calculated by the Cockcroft and Gault formula.

Outcomes
--------

Outcome data were obtained by telephone interview, follow-up letter or clinic visit. All events were carefully checked and verified by an independent group of clinical physicians. Investigator training, blinded questionnaire filling, and telephone recording were performed to achieve high-quality results. The primary endpoint was all-cause death. Secondary endpoints included cardiac death, major adverse cardiac and cerebrovascular events (MACCE), a composite of all-cause death, MI, stroke, or unplanned revascularization, and the individual components of the composite. All deaths were considered cardiac unless an unequivocal non-cardiac cause could be established.

Statistical Analysis
--------------------

A receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cut-off value of plasma big ET-1 for mortality prediction (**[Supplementary Fig. 1](#F4){ref-type="fig"}**). Participants were divided into high and low big ET-1 groups according to this cutoff value.

![Receiver operating characteristic (ROC) curve of big endothelin-1 for mortality prediction.](jat-26-959-g004){#F4}

Summary statistics were presented as frequency and percentage for categorical variables and mean ± standard deviation or median and interquartile range for continuous variables. An independent-sample Student\'s *t*-test or the Mann--Whitney *U*-test was performed for comparisons of continuous variables, and the Pearson chi-square test or Fisher\'s exact test was performed for comparison of categorical variables.

Survival curves were constructed by the Kaplan--Meier method and compared by the log-rank test. Univariable and multivariable Cox proportional hazards regressions were performed to calculate the hazard ratio (HR) and 95% confidence interval (CI) and evaluate the associations between big ET-1 level (as a categorical or continuous variable normalized by log~10~ transformation) and clinical outcomes. Covariates included in the multivariable model were age, sex, body mass index, hypertension, diabetes, previous MI, previous stroke, clinical presentation (stable angina pectoris \[SAP\] or acute coronary syndrome \[ACS\]), left main coronary artery involvement, left ventricular ejection fraction (LVEF), creatinine clearance, SS (≤ 22, 23--32, or ≥ 33), procedure (MT, PCI, or CABG), and aspirin. Patients who were lost to follow-up were censored at the last available contact.

Exploratory subgroup analyses of the primary outcome were performed according to age (\< 65 or ≥ 65 years), sex (male or female), diabetes (yes or no), presentation (SAP or ACS), left main involvement (yes or no), LVEF (\< 40% or ≥ 40%), SS (0--22, 23--32, or ≥ 33), and procedure (MT, PCI, or CABG). Interactions between plasma big ET-1 level (high or low) and these covariates were tested to interpret potential subgroup differences. The above-described multivariable Cox proportional hazards models were used for the interaction and subgroup analyses.

To assess the added prognostic value of big ET-1 for mortality prediction beyond the SSII, the C-index, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were calculated using R software version 3.4.3 (R Core Team, Vienna, Austria).

Two-sided *P*-values of \< 0.05 were considered statistically significant. Analyses were performed using SPSS software version 22.0 (IBM, Armonk, NY, USA) unless otherwise stated.

Results
=======

A total of 6,150 patients with available big ET-1 data were included in the present analysis. On the basis of the optimal cutoff value of 0.79 pmol/L, the patients were divided into low and high big ET-1 groups (**[Fig. 1](#F1){ref-type="fig"}**). At baseline, patients in the high big ET-1 group were older and had higher troponin I, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive protein, but lower LVEF and creatinine clearance (**[Table 1](#T1){ref-type="table"}**). Higher rates of female sex, hypertension, diabetes, previous MI, previous stroke, chronic kidney disease, and high SS were observed in the high big ET-1 group. Patients in the high big ET-1 group were more likely to receive MT alone rather than CABG and to take aspirin.

![Flowchart of subject selection.](jat-26-959-g001){#F1}

###### Baseline characteristics of the study population grouped by the optimal cutoff value of big endothelin-1

                                     Overall                Big ET-1 \< 0.79 pmol/L   Big ET-1 ≥ 0.79 pmol/L   *P*-value
  ---------------------------------- ---------------------- ------------------------- ------------------------ -----------
  Demographics                                                                                                 
      Age, year                      60.9 ± 10.0            60.5 ± 9.9                61.8 ± 10.2              \< 0.001
      Male                           4924 (80.1)            3367 (80.8)               1557 (78.5)              0.032
      BMI, kg/m^2^                   25.9 ± 3.1             25.8 ± 3.0                26.0 ± 3.1               0.192
  Medical history and risk factor                                                                              
      Hypertension                   4176 (67.9)            2785 (66.9)               1391 (70.1)              0.010
      Diabetes                       2189 (35.6)            1428 (34.3)               761 (38.4)               0.002
      Hyperlipidemia                 3691 (60.0)            2529 (60.7)               1162 (58.6)              0.110
      Previous MI                    2204 (35.8)            1454 (34.9)               750 (37.8)               0.027
      Previous stroke                646 (10.5)             406 (9.7)                 240 (12.1)               0.005
      COPD                           76 (1.2)               44 (1.1)                  32 (1.6)                 0.065
      PAD                            575 (9.3)              376 (9.0)                 199 (10.0)               0.206
      CKD                            57 (0.9)               24 (0.6)                  33 (1.7)                 \< 0.001
      Smoker                         3392 (55.2)            2300 (55.2)               1092 (55.0)              0.901
  Clinical characteristic                                                                                      
      SAP                            2406 (39.1)            1662 (39.9)               744 (37.5)               0.072
      ACS                            3744 (60.9)            2504 (60.1)               1240 (62.5)              0.072
      Left main involvement          1435 (23.3)            952 (22.9)                483 (24.3)               0.196
      LVEF, %                        58.3 ± 9.5             58.9 ± 8.9                57.2 ± 10.4              \< 0.001
      Big ET-1, pmol/L               0.65 (0.50--0.86)      0.56 (0.45--0.66)         1.05 (0.87--2.14)        \< 0.001
      Troponin I, ng/mL              0.03 (0.01--0.09)      0.02 (0.01--0.07)         0.03 (0.02--0.14)        \< 0.001
      NT-proBNP, pmol/L              632.0 (445.8--972.8)   596.1 (424.2--880.4)      715.4 (497.5--1241.4)    \< 0.001
      hsCRP, mg/L                    2.05 (1.00--5.45)      1.93 (0.96--4.70)         2.39 (1.08--6.93)        \< 0.001
      Creatinine clearance, mL/min   86.7 ± 27.5            87.9 ± 27.0               84.1 ± 28.5              \< 0.001
  Procedural characteristic                                                                                    
      SYNTAX score                                                                                             
          ≤ 22                       2255 (36.7)            1570 (38.7)               685 (35.8)               0.027
          23--32                     2271 (36.9)            1534 (37.8)               737 (38.5)               0.642
          ≥ 33                       1444 (23.5)            950 (23.4)                494 (25.8)               0.048
      Treatment                                                                                                
          MT                         1690 (27.5)            1073 (25.8)               617 (31.1)               \< 0.001
          PCI                        2576 (41.9)            1757 (42.2)               819 (41.3)               0.506
          CABG                       1884 (30.6)            1336 (32.1)               548 (27.6)               \< 0.001
  Medication at discharge                                                                                      
      Aspirin                        5908 (96.1)            4036 (96.9)               1872 (94.4)              \< 0.001
      Clopidogrel                    3328 (54.1)            2284 (54.8)               1044 (52.6)              0.105
      ACEI                           2215 (36.0)            1495 (35.9)               720 (36.3)               0.757
      ARB                            1013 (16.5)            671 (16.1)                342 (17.2)               0.264
      Beta-blocker                   5457 (88.7)            3694 (88.7)               1763 (88.9)              0.825
      CCB                            2097 (34.1)            1409 (33.8)               688 (34.7)               0.508
      Statin                         4149 (67.5)            2799 (67.2)               1350 (68.0)              0.502

Values are presented as mean ± standard deviation, median (interquartile range), or number (%).

ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; BMI, body mass index; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; hsCRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, peripheral artery disease.

The median follow-up was 6.8 (5.7--8.1) years, with a response rate of 82.0% (**[Fig. 1](#F1){ref-type="fig"}**). The baseline characteristics of the patients followed up and lost to follow-up are listed in **[Supplementary Table 1](#T4){ref-type="table"}**. All patients included in the analysis completed at least one follow-up. During the follow-up period, 818 (13.3%) patients experienced all-cause death. The median level of plasma big ET-1 was significantly higher in the patients who died (0.74 \[0.54--1.08\] pmol/L) than in those who survived (0.64 \[0.50--0.84\] pmol/L, *P* \< 0.001). Significantly more all-cause death, cardiac death, MACCE, and stroke occurred in the high big ET-1 group compared with the low big ET-1 group (all *P* % 0.05, **[Table 2](#T2){ref-type="table"}**).

###### Baseline characteristics of patients followed up and lost to follow up.

                                     Patients followed up   Patients lost to follow up   *P*-value
  ---------------------------------- ---------------------- ---------------------------- -----------
  Demographics                                                                           
      Age, year                      60.7 ± 9.9             62.0 ± 10.3                  \< 0.001
      Male                           4048 (80.3)            876 (79.2)                   0.429
      BMI, kg/m^2^                   25.9 ± 3.0             25.6 ± 3.3                   0.003
  Medical history and risk factor                                                        
      Hypertension                   3434 (68.1)            742 (67.1)                   0.522
      Diabetes                       1753 (34.8)            436 (39.4)                   0.003
      Hyperlipidemia                 3110 (61.7)            581 (52.5)                   \< 0.001
      Previous MI                    1748 (34.7)            456 (41.2)                   \< 0.001
      Previous stroke                505 (10.0)             141 (12.7)                   0.007
      COPD                           62 (1.2)               14 (1.3)                     0.920
      PAD                            456 (9.0)              119 (10.8)                   0.075
      CKD                            31 (0.6)               26 (2.4)                     \< 0.001
      Smoker                         2788 (55.3)            604 (54.6)                   0.688
  Clinical characteristic                                                                
      SAP                            1988 (39.4)            418 (37.8)                   0.318
      ACS                            3056 (60.6)            688 (62.2)                   0.318
      Left main involvement          1131 (22.4)            304 (27.5)                   \< 0.001
      LVEF, %                        58.7 ± 9.2             56.7 ± 10.3                  \< 0.001
      Big ET-1, pmol/L               0.65 (0.50--0.85)      0.68 (0.52--1.01)            \< 0.001
      Troponin I, ng/mL              0.03 (0.01--0.08)      0.03 (0.02--0.13)            \< 0.001
      NT-proBNP, pmol/L              622.2 (443.2--939.4)   690.9 (462.0--1228.1)        \< 0.001
      hsCRP, mg/L                    2.01 (0.98--5.27)      2.29 (1.05--6.19)            0.015
      Creatinine clearance, mL/min   87.5 ± 27.5            83.0 ± 27.4                  \< 0.001
  Procedural characteristic                                                              
      SYNTAX score                                                                       
          ≤ 22                       1905 (37.8)            350 (31.6)                   \< 0.001
          23--32                     1841 (36.5)            430 (38.9)                   0.137
          ≥ 33                       1148 (22.8)            296 (26.8)                   0.004
      Treatment                                                                          
          MT                         1295 (25.7)            395 (35.7)                   \< 0.001
          PCI                        2168 (43.0)            408 (36.9)                   \< 0.001
          CABG                       1581 (31.3)            303 (27.4)                   0.010
  Medication at discharge                                                                
      Aspirin                        4871 (96.6)            1037 (93.8)                  \< 0.001
      Clopidogrel                    2758 (54.7)            570 (51.5)                   0.058
      ACEI                           1801 (35.7)            414 (37.4)                   0.279
      ARB                            816 (16.2)             197 (17.8)                   0.185
      Beta-blocker                   4469 (88.6)            988 (89.3)                   0.486
      CCB                            1681 (33.3)            416 (37.6)                   0.006
      Statin                         3388 (67.2)            761 (68.8)                   0.292

Values are presented as mean ± standard deviation, median (interquartile) or number (%).

ACEI, angiotensin-converting enzyme inhibitors; ACS, acute coronary syndrome; ARB, angiotensin II receptor blockers; BMI, body mass index; CABG, coronary artery bypass grafting; CCB, calcium channel blocker; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ET-1, endothelin-1; hsCRP, high sensitivity C reactive protein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MT, medical therapy; NT-proBNP, N-terminal pro-B-Type natriuretic peptide; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; SAP, stable angina pectoris.

###### Risks of primary and secondary outcomes

  Outcome                       No. of Patients with event (%)   Crude HR (95% CI)   Crude *P*-value   Adjusted HR (95% CI)   Adjusted *P*-value
  ----------------------------- -------------------------------- ------------------- ----------------- ---------------------- --------------------
  All-cause death                                                                                                             
      Low big ET-1              443 (10.6)                       Reference                             Reference              
      High big ET-1             375 (18.9)                       1.69 (1.47--1.94)   \< 0.001          1.38 (1.19--1.59)      \< 0.001
      log(big ET-1)             --                               1.93 (1.55--2.40)   \< 0.001          1.43 (1.13--1.80)      0.002
  Cardiac death                                                                                                               
      Low big ET-1              231 (5.5)                        Reference                             Reference              
      High big ET-1             204 (10.3)                       1.75 (1.44--2.11)   \< 0.001          1.37 (1.13--1.67)      0.002
      log(big ET-1)             --                               2.11 (1.57--2.85)   \< 0.001          1.53 (1.11--2.10)      0.009
  MACCE                                                                                                                       
      Low big ET-1              1067 (25.6)                      Reference                             Reference              
      High big ET-1             695 (35.0)                       1.32 (1.20--1.45)   \< 0.001          1.20 (1.09--1.32)      \< 0.001
      log(big ET-1)             --                               1.38 (1.18--1.62)   \< 0.001          1.20 (1.02--1.42)      0.027
  Myocardial infarction                                                                                                       
      Low big ET-1              180 (4.3)                        Reference                             Reference              
      High big ET-1             105 (5.3)                        1.13 (0.88--1.44)   0.335             1.12 (0.88--1.44)      0.358
      log(big ET-1)             --                               1.01 (0.69--1.48)   0.969             1.02 (0.69--1.50)      0.931
  Stroke                                                                                                                      
      Low big ET-1              266 (6.4)                        Reference                             Reference              
      High big ET-1             155 (7.8)                        1.17 (0.96--1.43)   0.116             1.12 (0.92--1.38)      0.265
      log(big ET-1)             --                               1.13 (0.81--1.57)   0.469             1.06 (0.75--1.48)      0.746
  Unplanned revascularization                                                                                                 
      Low big ET-1              321 (7.7)                        Reference                             Reference              
      High big ET-1             167 (8.4)                        1.11 (0.92--1.34)   0.264             1.11 (0.92--1.35)      0.277
      log(big ET-1)             --                               1.08 (0.77--1.49)   0.663             1.12 (0.81--1.56)      0.494

Univariable analysis showed that high big ET-1 level was associated with higher risks of all-cause death, cardiac death, and MACCE, but not MI, stroke, or unplanned revascularization (**[Table 2](#T2){ref-type="table"}**). After adjustment for covariates, high big ET-1 level remained an independent risk factor for all-cause death (HR: 1.36, 95% CI: 1.18--1.57, *P* \< 0.001), cardiac death (HR: 1.36, 95% CI: 1.12 --1.66, *P* = 0.002), and MACCE (HR: 1.19, 95% CI: 1.08--1.31, *P* = 0.001). **[Fig. 2](#F2){ref-type="fig"}** shows the Kaplan--Meier estimates for the primary and secondary endpoints (log-rank *P* \< 0.001 for all-cause death, cardiac death, and MACCE).

![Cumulative incidence curves for primary and secondary endpoints.\
(A--F) Cumulative incidences of all-cause death (A), cardiac death (B), MACCE (C), myocardial infarction (D), stroke (E), and unplanned revascularization (F).](jat-26-959-g002){#F2}

The relationship of big ET-1 level (high or low) with all-cause death was relatively consistent across the subgroups of age, sex, diabetes, presentation, left main disease, LVEF, SS, and procedure (**[Fig. 3](#F3){ref-type="fig"}**). There were no significant interactions between big ET-1 levels and these covariates (interaction *P* \> 0.1 for all subgroups).

![Subgroup analyses for the primary endpoint.\
HRs and 95% CIs were calculated by reference to the low big ET-1 group. The interaction between big ET-1 level and each covariate was tested by a multivariable Cox proportional hazards regression model.](jat-26-959-g003){#F3}

When big ET-1 level (high or low) was combined with the SSII for mortality prediction, there were significant improvements in C-index (0.723 \[0.704--0.742\] vs. 0.715 \[0.697--0.734\], *P* = 0.029), NRI (0.304 \[0.229--0.378\], *P* \< 0.001), and IDI (0.009 \[0.006--0.012\], *P* \< 0.001) compared with the SSII alone (**[Table 3](#T3){ref-type="table"}**).

###### Additional prognostic information provided by big endothelin-1 level beyond SSII

                    C-index (95% CI)       *P*-value   NRI (95% CI)           *P*-value   IDI (95% CI)           *P*-value
  ----------------- ---------------------- ----------- ---------------------- ----------- ---------------------- -----------
  SSII              0.715 (0.697--0.734)   Reference   --                     Reference   --                     Reference
  SSII + big ET-1   0.723 (0.704--0.742)   0.029       0.304 (0.229--0.378)   \< 0.001    0.009 (0.006--0.012)   \< 0.001

Discussion
==========

The study shows that (i) high plasma big ET-1 level is an independent risk factor for all-cause death, cardiac death, and MACCE and is relatively consistent across subgroups and (ii) plasma big ET-1 level improves predictability of the SSII for long-term mortality in patients with TVD.

Plasma big ET-1 level has been identified as a novel marker of disease severity and clinical outcome in the context of CAD. Big ET-1 level was a predictor of severity in stable CAD, as reflected by the Gensini score^[@bib9])^. Moreover, two cohort studies found that high big ET-1 level was associated with increased risks of adverse outcomes in patients with stable CAD^[@bib8],\ [@bib10])^. In another cohort study of 983 patients with acute MI, big ET-1 level was an independent predictor of death or heart failure, with an area under the ROC curve of 0.76^[@bib7])^. These studies demonstrated that higher level of big ET-1 was associated with higher risks of adverse events in stable CAD or ACS, in accordance with the present study performed in SAP and ACS patients. The present study further extended the association to the setting of TVD with heavy atherosclerotic burden.

Revascularization (PCI or CABG) has been considered to improve prognosis in patients with multivessel disease compared with MT alone^[@bib13])^. It remains unknown whether there is an interaction between treatment (MT, PCI, or CABG) and big ET-1 level with outcomes. In our study, the association between big ET-1 level and mortality was relatively consistent across patients receiving MT, PCI, and CABG, with no significant interaction between big ET-1 level and treatment. Thus, high big ET-1 level remained an independent risk marker for mortality regardless of whether or not revascularization was performed.

ET-1 contributes to the poor prognosis in TVD patients through several mechanisms. First, as a vasoconstrictor, ET-1 accounts for nearly all the resting tone in atherosclerotic coronary arteries^[@bib14])^. High ET-1 level can lead to vasoconstriction and decreased coronary blood flow, which may induce or aggravate myocardial ischemia. Second, ET-1 can decrease nitric oxide (NO) production and increase NO degradation, leading to an imbalance between NO and ET-1 and subsequent endothelial dysfunction in the coronary circulation^[@bib15])^. Third, ET-1 can promote increases in oxidative stress and inflammatory cell infiltration, which contribute to atherosclerotic plaque formation, progression, and rupture^[@bib16])^. These effects can be even more significant and more likely to lead to adverse events in the setting of TVD with heavy atherosclerotic burden in all three major vessels. Compared with traditional biomarkers representing myocardial injury (troponin I), cardiac stress (N-terminal pro-B-type natriuretic peptide), and inflammation (high-sensitivity C-reactive protein), big ET-1 can reflect endothelial function that is important for the development of atherosclerosis^[@bib4])^.

TVD is present in 20%--30% of patients with obstructive CAD^[@bib17],\ [@bib18])^. As a severe type of CAD, it confers an almost two-fold higher risk of mortality compared with single-vessel disease^[@bib1])^. Calculation of the SS is recommended for assessment of the long-term mortality risk in TVD patients^[@bib19])^ but showed only modest predictability in previous studies^[@bib20],\ [@bib21])^. Despite the generally better performance of the SSII compared with the SS, some studies found only a moderate discrimination ability of the SSII for long-term mortality prediction in patients with multivessel disease^[@bib22],\ [@bib23])^. Biomarkers have been shown to provide additional prognostic information beyond clinical characteristics in CAD^[@bib24])^. Addition of biomarkers to the SSII may enhance its predictability, because it is mainly based on clinical characteristics. Our study demonstrated significant improvements in the C-index, NRI, and IDI after incorporation of big ET-1 level into the SSII, indicating better predictive performance compared with the SSII alone. These findings are of great importance because better risk stratification can be achieved for guidance of treatment. Furthermore, similar to the traditional biomarkers, measurement of plasma big ET-1 is simple and economic using a commercial immunoassay. Although more evidence is needed regarding the prognostic value of big ET-1 level, our study has shown the feasibility of its addition to the established model to improve predictability.

There are some limitations that should be noticed in this study. First, this was an observational study that may suffer from potential selection and measurement biases. Second, all participants in the study were enrolled from a single specialized center for cardiovascular disease, which may limit the reliability and generalizability of our findings. Third, angiographic criteria were used as the main indications for revascularization, and physiological tests were only performed when a treatment decision could not be made using the angiographic findings alone. As a result, most of the participants in our study did not undergo preprocedural/intraprocedural ischemia evaluations. Fourth, the present analyses were based on a single plasma big ET-1 measurement, and thus, potential fluctuations in its levels remain uncountable.

Conclusions
===========

In patients with TVD, plasma big ET-1 level was significantly higher in patients who died during follow-up than those who survived. Higher big ET-1 level was independently associated with increased risks of all-cause death, cardiac death, and MACCE. Big ET-1 level improves the discrimination and reclassification of the SSII to predict long-term mortality.
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